ALK mutations have been associated with poorer survival in high-risk neuroblastoma, and ALK gene is amplified in a subgroup of MYCN-amplified neuroblastoma tumors due to the proximity of the two loci (2p23-24) at the 2p-gain region associated with high-risk neuroblastoma (De Brouwer et al., 2010; Bresler et al., 2014). The gene discussed is MYCN; the disease is neuroblastoma.